Molnupiravir Provider Checklist

	Positive SARS-CoV-2 test
	Age ≥18 years
	Alternate COVID-19 treatment options authorized by FDA are not accessible or clinically appropriate
	High-risk criteria met
	Symptoms consistent with mild-moderate COVID-19
	Symptom onset with 5 days*
	Not hospitalized due to COVID-19
	Assessment pregnancy and breastfeeding status (if applicable)
	 Provide appropriate counseling Females of childbearing potential treated: should use a reliable method of contraception correctly and consistently, as applicable, for the <u>duration of treatment and for 4 days after the last dose of molnupiravir</u> Breastfeeding is not recommended for the <u>duration of treatment and for 4 days after the last dose of molnupiravir</u>
	 Males of reproductive potential treated: if sexually active with females of childbearing potential, should use a reliable method of contraception correctly and consistently <u>during treatment and for at least 3 months after the last dose</u>
*Prescriber is encouraged to include a note to the pharmacist in the prescription stating:	
	ease fill prescription by <u>[insert date]</u> . This prescription fill by date is within 5 days from symptom onset do complies with the patient eligibility criteria under the EUA.